Eagle Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 21 2022 - 3:30PM
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the
“Company”) today announced that Scott Tarriff, Chief Executive
Officer, and Brian Cahill, Chief Financial Officer, will present at
the 41
st Annual J.P. Morgan Healthcare Conference
as follows:
Date: |
Tuesday,
January 10, 2023 |
Time: |
10:30AM PT/1:30PM ET |
Webcast: |
Click Here |
The webcast of the presentation will be accessible for 30 days
thereafter, via the Company’s website at www.eagleus.com, under the
Investors section.
About Eagle Pharmaceuticals, Inc. Eagle is a
fully integrated pharmaceutical company with research and
development, clinical, manufacturing and commercial expertise.
Eagle is committed to developing innovative medicines that result
in meaningful improvements in patients’ lives. Eagle’s
commercialized products include vasopressin, PEMFEXY®, RYANODEX®,
BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and BARHEMSYS®
through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s
oncology and CNS/metabolic critical care pipeline includes product
candidates with the potential to address underserved therapeutic
areas across multiple disease states. Additional information is
available on Eagle’s website at www.eagleus.com.
Investor Relations for Eagle Pharmaceuticals,
Inc.: Lisa M. WilsonIn-Site Communications, Inc. T:
212-452-2793 E: lwilson@insitecony.com
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
From Apr 2024 to May 2024
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
From May 2023 to May 2024